ID: ALA3397797

Max Phase: Preclinical

Molecular Formula: C25H27NO4

Molecular Weight: 405.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  Oc1cc(O)cc(CN[C@@H]2CO[C@H](C(c3ccccc3)c3ccccc3)C[C@H]2O)c1

Standard InChI:  InChI=1S/C25H27NO4/c27-20-11-17(12-21(28)13-20)15-26-22-16-30-24(14-23(22)29)25(18-7-3-1-4-8-18)19-9-5-2-6-10-19/h1-13,22-29H,14-16H2/t22-,23-,24+/m1/s1

Standard InChI Key:  LTYHUAMWNDMPOK-SMIHKQSGSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 405.49

Molecular Weight (Monoisotopic): 405.1940

AlogP: 3.54

#Rotatable Bonds: 6

Polar Surface Area: 81.95

Molecular Species: NEUTRAL

HBA: 5

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.16

CX Basic pKa: 7.54

CX LogP: 3.60

CX LogD: 3.37

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.50

Np Likeness Score: 0.63

References

1. Santra S, Sharma H, Vedachalam S, Antonio T, Reith M, Dutta A..  (2015)  Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.,  23  (4): [PMID:25593099] [10.1016/j.bmc.2014.12.040]

Source

Source(1):

• Scientific Literature